

**POLICY:** Enzyme Replacement Therapy – Fabrazyme Utilization Management Medical Policy

- Fabrazyme® (agalsidase intravenous infusion – Genzyme)

**EFFECTIVE DATE:** 1/1/2021

**LAST REVISION DATE:** 04/16/2025

**COVERAGE CRITERIA FOR:** All Aspirus Medicare Plans

---

### **OVERVIEW**

Fabrazyme, a human  $\alpha$ -galactosidase A ( $\alpha$ -Gal), is indicated for **Fabry disease**.<sup>1</sup> It is the same amino acid sequence as the native enzyme and is produced in Chinese hamster ovary cells via recombinant DNA technology. Fabrazyme catalyzes the breakdown of globotriaosylceramide (GL-3) and other  $\alpha$ -galactyl-terminated neutral glycosphingolipids to ceramide and galactose and reduces the deposition of GL-3 in the capillary endothelium of the kidney and certain other cell types.

### **Disease Overview**

Fabry disease is a rare inherited X-linked lysosomal storage disorder due to absent or significantly reduced  $\alpha$ -Gal activity leading to the accumulation of GL-3 in a wide variety of cells throughout the body.<sup>2-4</sup> The accumulation of GL-3 leads to progressive multisystem disease, primarily impacting the kidney, heart, and nervous system.<sup>3,4</sup> The incidence of Fabry disease is estimated to be about 1:117,000 live male births.<sup>2</sup> Fabry disease can be divided into two phenotypes. A severe, classical phenotype typically occurs in men without  $\alpha$ -Gal activity, whereas a generally milder non-classical phenotype is found in men and women with some residual  $\alpha$ -Gal activity.<sup>2,3</sup> The diagnosis of Fabry disease can be confirmed in males by demonstrating a deficiency in  $\alpha$ -Gal activity, and in all patients by identifying a Fabry disease causing gene mutation.<sup>4</sup> Long-term consequences of Fabry disease include hypertrophic cardiomyopathy, arrhythmias, renal failure, and stroke.<sup>3</sup> The kidney disease that occurs in Fabry disease is associated with progressive proteinuria and a decline in glomerular filtration rate, which over time, leads to end-stage renal disease requiring dialysis and ultimately, kidney transplantation.<sup>2</sup> Treatment with Fabrazyme reduces the accumulation of GL-3 in the kidney (and in other organs), with the goal of stopping or slowing the decline in kidney function.

### **POLICY STATEMENT**

Prior Authorization is recommended for medical benefit coverage of Fabrazyme. Approval is recommended for those who meet the **Criteria** and **Dosing** for the listed indication. Extended approvals are allowed if the patient continues to meet the Criteria and Dosing.

Requests for doses outside of the established dosing documented in this policy will be considered on a case-by-case basis by a clinician (i.e., Medical Director or Pharmacist). All approvals are provided for the duration noted below. Because of the specialized skills required for evaluation and diagnosis of patients treated with Fabrazyme as well as the monitoring required for adverse events and long-term efficacy, approval requires Fabrazyme to be prescribed by or in consultation with a physician who specializes in the condition being treated.

**Automation:** None.

#### **RECOMMENDED AUTHORIZATION CRITERIA**

Coverage of Fabrazyme is recommended in those who meet the following criteria:

#### **FDA-Approved Indication**

---

**1. Fabry Disease.** Approve for 1 year if the patient meets BOTH of the following (A and B):

**A)** The diagnosis is established by ONE of the following (i or ii):

- i.** Patient has a laboratory test demonstrating deficient  $\alpha$ -galactosidase A activity in leukocytes or fibroblasts; OR
- ii.** Patient has a molecular genetic test demonstrating a pathogenic variant in the galactosidase alpha gene (GLA); AND

**B)** Fabrazyme is prescribed by or in consultation with a geneticist, endocrinologist, a metabolic disorder sub-specialist, or a physician who specializes in the treatment of lysosomal storage disorders.

**Dosing.** Each dose must not exceed 1 mg/kg administered intravenously no more frequently than once every 2 weeks.

---

#### **CONDITIONS NOT RECOMMENDED FOR APPROVAL**

Coverage of Fabrazyme is not recommended in the following situations:

**1. Concurrent Use with Galafold® (migalastat oral capsules).** One small study (n = 23) assessed a single dose of Galafold (150 mg or 450 mg) used concurrently with Fabrazyme or agalsidase alfa.<sup>5</sup> While a single dose of Galafold significantly increased  $\alpha$ -Gal activity, the long-term safety and efficacy of concurrent use of Galafold and Fabrazyme has not been established. Galafold is not FDA approved for concurrent use with Fabrazyme.

**2. Concurrent Use with Elfabrio® (pegunigalsidase alfa intravenous infusion).**

3. Coverage is not recommended for circumstances not listed in the Recommended Authorization Criteria. Criteria will be updated as new published data are available.

## REFERENCES

1. Fabrazyme® intravenous infusion [prescribing information]. Cambridge, MA: Genzyme; May 2024.
2. Schiffmann R. Fabry Disease. *Handb Clin Neurol*. 2015;132:231-248.
3. Arends M, Wanner C, Hughes D, et al. Characterization of Classical and Nonclassical Fabry Disease: A Multinational Study. *J Am Soc Nephrol*. 2017;28:1631-1641.
4. Laney DA, Bennett RL, Clarke V, et al. Fabry Disease Practice Guidelines: Recommendations of the National Society of Genetic Counselors. *J Genet Counsel*. 2013;22:555-564.
5. Warnock DG, Bichet DG, Holida M, et al. Oral Migalastat HCl Leads to Greater Systemic Exposure and Tissue Levels of Active  $\alpha$ -Galactosidase A in Fabry Patients when Co-Administered with Infused Agalsidase. *PLoS ONE*. 2015;10:e0134341.

## HISTORY

Type of Revision	Summary of Changes	Review Date
Annual Revision	No criteria changes.	04/12/2023
Annual Revision	<b>Fabry Disease:</b> For diagnosis confirmed by genetic testing, the term “mutation” was rephrased to “pathogenic variant.” Conditions not recommended for approval were added and include concurrent use with Galafold® (migalastat oral capsules) and concurrent use with Elfabrio® (pegunigalsidase alfa intravenous infusion).	04/19/2024
Aspirus P&T Review	Policy reviewed and approved by Aspirus P&T committee. Annual review process	09/16/2024
Annual Revision	No criteria changes.	04/16/2025